Paul Chamberlin

Paul Chamberlin is a seasoned clinical development leader currently serving as Vice President of Clinical Development at Anthos Therapeutics, where responsibilities include oversight of the novel Factor XI inhibitor, abelacimab, for preventing venous thromboembolism in cancer patients. Previously, Paul held the position of Head of Clinical Development at Imbria Pharmaceuticals, advancing the cardiovascular drug ninerafaxstat across various indications. As Senior Medical Director at Ironwood Pharmaceuticals, Paul was involved in both early and late-phase clinical development of sGC stimulator compounds for gastrointestinal and central nervous system disorders. Paul also served as Chief Medical Officer at Ventrix, Inc., managing clinical development and regulatory affairs related to a biologic for heart failure treatment. Additionally, Paul has offered consulting services at Prism Biolabs. Academic qualifications include a Bachelor of Arts from the University of Pennsylvania and a Doctor of Medicine from Boston University School of Medicine.